# A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

> **NCT03518073** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 360 (actual)

## Conditions studied

- Alzheimer Disease (AD)

## Interventions

- **DRUG:** Zagotenemab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03518073
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-30
- **Primary completion:** 2021-08-23
- **Final completion:** 2021-10-25
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2022-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03518073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03518073, "A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03518073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*